Intro; Preface to the First Edition; Preface to the Second Edition; Contents; 1: Drug Interactions and Pharmacogenetics; 1.1 Introduction; 1.2 Principles of Drug Interactions; 1.2.1 Physical Interactions or Chemical Incompatibilities; 1.2.1.1 pH Effects; 1.2.1.2 Solubilizers; 1.2.1.3 Plasticizers; 1.2.1.4 Sorption; 1.2.2 Chemical Reactions; 1.2.3 Denaturation; 1.2.4 Pharmacokinetic Interactions; 1.2.4.1 Absorption; 1.2.4.2 Ionization; 1.2.5 Complexation; 1.2.5.1 Contact with the Digestive Mucosa; 1.2.5.2 Gastrointestinal Motility; Modifications in Drug Diffusion

1.2.6 Binding to Plasma Proteins1.2.6.1 Modification of the Tissue Binding; Metabolic Interactions; Modifications in the Elimination; Miscellaneous; 1.2.7 Pharmacodynamic Interactions; 1.2.7.1 Terminology; 1.2.7.2 Synergy and Antagonism; 1.2.7.3 Enhancement and Antagonism; 1.3 Interactions Between Anticancer Drugs and Other Active Substances; 1.3.1 Antiemetics; 1.3.1.1 Chlorpromazine; 1.3.1.2 Metoclopramide; 1.3.1.3 Granisetron and Ondansetron; 1.3.2 Antiulcer Drugs; 1.3.3 Analgesics (Nonsteroidal Anti-inflammatory Drugs); 1.3.4 Antimicrobial Agents; 1.3.5 Miscellaneous

1.4 Anticancer Drug-Anticancer Drug Interactions1.4.1 Modulation; 1.4.2 Undesired Drug Interactions; 1.5 Drug Interactions Between Anticancer Drugs and Resistance-Modifying Agents; 1.6 Pharmacogenetics; 1.7 Summary; References; 2: Breast Cancer; 2.1 Introduction; 2.2 Chemotherapy; 2.2.1 Classes of Chemotherapy and General Toxicities; 2.2.1.1 Anti-microtubule Agents (Taxanes, Ixabepilone, Eribulin, and Vinca Alkaloids); 2.2.1.2 Anthracyclines (Doxorubicin, Epirubicin, Mitoxantrone, Liposomal Doxorubicin, and Non-pegylated Liposomal Doxorubicin)

2.2.1.3 Antimetabolites (5-Fluorouracil, Methotrexate, Capecitabine, and Gemcitabine)2.2.1.4 Alkylating Agents (Cyclophosphamide, Cisplatin, and Carboplatin); 2.2.1.5 Dose-Dense Chemotherapy; 2.2.2 Incidence and Management of Selected Chemotherapy Toxicities; 2.2.2.1 Febrile Neutropenia; 2.2.2.2 Management of Chemotherapy-Induced Emesis; 2.2.2.3 Peripheral Neuropathy; 2.2.2.4 Cardiac Failure; 2.2.2.5 Gastrointestinal Side Effects: Mucositis, Diarrhea, and Constipation; 2.2.2.6 Cognitive Dysfunction; 2.2.2.7 Altered Body Image and Sexual Dysfunction; 2.2.2.8 Fertility

2.2.2.9 Secondary Malignancies2.3 Endocrine Therapies; 2.3.1 Gynecological Side Effects; 2.3.2 Thromboembolic Disease; 2.3.3 Hot Flashes; 2.3.4 Eye Problems; 2.3.5 Musculoskeletal Pain; 2.3.6 Bone Loss; 2.3.7 Cardiovascular Events; 2.3.8 Cognitive Dysfunction; 2.4 Targeted Agents; 2.4.1 Cardiovascular Toxicity; 2.4.2 Hypertension; 2.4.3 Infusion Reactions; 2.4.4 Hepatotoxicity; 2.4.5 Gastrointestinal Perforation, Wound-Healing Complications, and Bleeding; 2.4.6 Diarrhea; 2.4.7 Skin Rash; 2.4.8 Interstitial Pneumonitis; 2.4.9 Hematological Toxicity